Online inquiry

IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9371MR)

This product GTTS-WQ9371MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets IL2R gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000417.3; NM_000878.5; NM_000206.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559; 3560; 3561
UniProt ID P01589; P14784; P31785
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9371MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3461MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AZD8895
GTTS-WQ11152MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-1333
GTTS-WQ1177MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABP 501
GTTS-WQ4595MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ12486MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA NN-8226
GTTS-WQ6074MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 888
GTTS-WQ14548MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ9054MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMC-18F1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW